Cfo4 Life Group, LLC Savara Inc Transaction History

Cfo4 Life Group, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 15, 2020	SELL	$1.8 - $3.05 $38,320 - $64,931	-21,289 Closed	0 $0
Q4 2019 Jan 22, 2020	BUY	$0.71 - $4.91 $4,970 - $34,370	7,000 Added 48.99%	21,289 $95,000
Q2 2019 Jul 29, 2019	BUY	$2.37 - $11.7 $7,110 - $35,100	3,000 Added 26.57%	14,289 $34,000
Q1 2018 May 07, 2018	BUY	$8.99 - $14.95 $101,488 - $168,770	11,289 New	11,289 $104,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $389M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Cfo4 Life Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Cfo4 Life Group, LLC with notifications on news.